Stock Analysis

Have Insiders Sold uniQure N.V. (NASDAQ:QURE) Shares Recently?

  •  Updated
NasdaqGS:QURE
Source: Shutterstock

We wouldn't blame uniQure N.V. (NASDAQ:QURE) shareholders if they were a little worried about the fact that Matthew Kapusta, the CEO, CFO & Executive Director recently netted about US$1.2m selling shares at an average price of US$36.63. That sale reduced their total holding by 14% which is hardly insignificant, but far from the worst we've seen.

See our latest analysis for uniQure

The Last 12 Months Of Insider Transactions At uniQure

Notably, that recent sale by Matthew Kapusta is the biggest insider sale of uniQure shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of US$35.41. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

In the last year uniQure insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
NasdaqGS:QURE Insider Trading Volume February 1st 2021

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

Insider Ownership of uniQure

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. uniQure insiders own about US$12m worth of shares. That equates to 0.8% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About uniQure Insiders?

Insiders sold uniQure shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. We'd practice some caution before buying! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Our analysis shows 5 warning signs for uniQure (1 is a bit concerning!) and we strongly recommend you look at them before investing.

But note: uniQure may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you’re looking to trade uniQure, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


What are the risks and opportunities for uniQure?

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.

View Full Analysis

Rewards

  • Trading at 89.1% below our estimate of its fair value

  • Revenue is forecast to grow 37.82% per year

Risks

  • Significant insider selling over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report